Due to their rapid metastatic spread, pancreatic tumours are among the most aggressive types of cancer.

Only three to five percent of patients have a survival rate of five years.

A team of KIT researchers has now established the basis for new therapeutic approaches.

In the Gastroenterology journal they report that in various pancreatic cancer mouse models CD44v6-specific peptides do not only inhibit the spread of tumour cells, but may even lead to the regression of already existing metastases. 

“We think that these peptides have a high potential for tumour therapy, above all for the treatment of pancreatic cancer with its aggressive metastases,” Véronique Orian-Rousseau of the Institute of Toxicology and Genetics (ITG) of KIT says. The CD44v6 protein was discovered in the 1990s by KIT.

It acts as a co-receptor for so-called receptor tyrosine kinases, such as MET or VEGFR-2, that depend on CD44 for their activation.

These enzymes largely influence the activities of tumour cells.

MET accelerates their proliferation, migration, and invasion.

VEGFR-2 promotes angiogenesis, i.e. the formation of new blood vessels required to supply the tumour.

Hence, they are decisive for the growth and spread of tumour cells.

In pre-clinical studies on animals and using various pancreatic cancer models, KIT scientists proved for the first time that the co-receptor function of CD44v6 drives the metastatic spreading.

Interestingly, small segments of the CD44v6 protein (called v6pep) turned out to be successful inhibitors of metastasis in animal experiments.

The researchers assume that they interfere with the three-dimensional protein structure of CD44v6 and inactivate it in this way.

Peptide treatment of tumour-bearing animals led to a reduction of tumour load and to the inhibition of metastasis.

Moreover, already existing metastases regressed or disappeared completely: “This is the most remarkable result with respect to pancreatic cancer, the diagnosis of which mostly is possible after the formation of metastases only,” Orian-Rousseau says.

In the animal experiments the survival time increased dramatically.

The v6pep peptides were found to be much more effective than Crizotinib and Pazopanib, tyrosine kinase inhibitors directed against MET and VEGFR2 respectively.

The evaluation of data of patients suffering from pancreatic cancer shows that metastasis and shorter survival times correlate with an increased level of CD44v6 and MET.

“This means that we have made an important step forward in basic research that will help the development of anti-cancer drugs,” the scientist explains.

Clinical studies that are planned to be made in cooperation with the KIT spinoff “amcure GmbH” in late 2016 will reveal whether the peptides will be effective in human patients.

Reference

Alexandra Matzke-Ogi et al. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference with CD44v6 Signaling, Gastroenterology, 2015

Source: Karlsruhe Institute of Technology